Bristol-Myers Squibb And Pfizer Provide Update On Apixaban Clinical Development Program

Posted by Pharma Industry / Biotech Industry News From Medical News Today

August 28, 2008

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc (NYSE: PFE) provided an update on the apixaban clinical development program today. The companies announced that new Phase II data in acute coronary syndrome patients (ACS) will be presented at the upcoming meeting of the European Society of Cardiology (ESC).